Alto Neuroscience secures $120M to advance novel depression therapy ALTO-207 through Phase 3 trials, aiming for FDA ...
Depression-related fatigue is caused by cellular "overworking" at rest and a failure to produce energy under stress.
Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported ...
The bipolar depression market is anticipated to increase during the forecast period (2026--2036), owing to the rise in the launch of emerging therapies such as Azetukalner (Xenon Pharmaceuticals), ...
Flow's FL-100 device is expected to be available in the US as soon as Q2 2026. Image credit: Tada Images via Shutterstock.com. The US Food and Drug Administration (FDA) has cleared Flow Neuroscience’s ...
On Tuesday, Alto Neuroscience, Inc. (NASDAQ:ANRO) announced an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of dopamine agonist drug combinations for ...
Alto Neuroscience (ANRO) has announced a private placement financing (PIPE) agreement to raise approximately $120 million before expenses. The financing is led by Commodore Capital with support from ...
-- Met Primary Endpoint with 30mg Dose of RE104 with 23.0-Point Total Score Reduction in Montgomery-Åsberg Depression Rating Scale (MADRS) on Day 7 (p=0.0094) -- -- Demonstrated Rapid and Durable ...
Hyperarousal plays an important role in mental disorders. It influences the severity of insomnia, depression, anxiety, ...
Almost half of people with depression meet criteria for being ‘treatment-resistant’, found a new study published in the British Journal of Psychiatry. Definitions for treatment-resistant depression ...
People with depression tend to prefer carbohydrate-rich foods, according to a new study published in Psychological Medicine. The findings point toward the possibility of dietary therapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results